YZYangyang Zhang

Yangyang Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yangyang Zhang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Path to Constraints on Common Envelope Ejection in Massive Binaries: Full Evolutionary Reconstruction of Three Black Hole X-Ray Binaries

    by Zhenwei Li, Dandan Wei, Shi Jia, Hailiang Chen, Hongwei Ge, Zhuo Chen, Yangyang Zhang, Xuefei Chen, Zhanwen Han

    The massive binary common envelope (CE) phase plays a pivotal role in the formation of close black hole (BH)/neutron star binaries, yet significant uncertainties remain in our understanding of this process. In this study, we aim to constrain the massive binary CE phase by systematically reconstructing three observed BH X-ray binaries (BHXBs): GRO J1655-40, SAX J1819.3-2525, and 4U 1543-47. Through comprehensive binary evolution simulations and parametric supernova modeling, we establish lower limits for the CE efficiency parameters under different energy considerations within the standard energy formalism. Specifically, we derive minimum values for three cases: α 0.5U and α U , representing CE efficiencies with half and all of the internal energy contributing to the envelope ejection, respectively, and α H , accounting for the envelope’s enthalpy. Our analysis reveals that the self-consistent formation of these three BHXBs requires CE efficiency parameters satisfying α 0.5U ≳ 6.7, α U ≳ 4.2, and α H ≳ 1.7. Notably, we find no viable solutions with CE efficiency values below unity, even when considering the most extreme scenarios, in which the envelope binding energy is significantly reduced through enthalpy inclusion. Our results strongly imply that either additional energy sources are required or the formalism itself must be revised. Furthermore, we quantitatively assess the impact of BH natal kicks on our results. A key finding is that 4U 1543-47’s formation requires substantial natal kicks (≳50 km s −1 ), as lower kick velocities are incompatible with isolated binary evolution.


  • Open Access

    Abplatin(IV) inhibited tumor growth on a patient derived cancer model of hepatocellular carcinoma and its comparative multi-omics study with cisplatin

    by Xing Li, Lingpu Zhang, Tuo Li, Shumu Li, Wenjing Wu, Lingyu Zhao, Peng Xie, Jinqi Yang, Peipei Li, Yangyang Zhang, et al.

    Background: Cisplatin, the alkylating agent of platinum(II) (Pt(II)), is the most common antitumor drug in clinic; however, it has many side effects, therefore it is higly desired to develop low toxicity platinum(IV) (Pt(IV)) drugs. Multi-omics analysis, as a powerful tool, has been frequently employed for the mechanism study of a certain therapy at the molecular level, which might be helpful for elucidating the mechanism of platinum drugs and facilitating their clinical application. Methods: Strating form cisplatin, a hydrophobic Pt(IV) prodrug (CisPt(IV)) with two hydrophobic aliphatic chains was synthesized, and further encapsulated with a drug carrier, human serum albumin (HSA), to form nanoparticles, namely AbPlatin(IV). The anticancer effect of AbPlatin(IV) was investigated in vitro and in vivo. Moreover, transcriptomics, metabolomics and lipidomics were performed to explore the mechanism of AbPlatin(IV). Results: Compared with cisplatin, Abplatin(IV) exhibited better tumor-targeting effect and greater tumor inhibition rate. Lipidomics study showed that Abplatin(IV) might induce the changes of BEL-7404 cell membrane, and cause the disorder of glycerophospholipids and sphingolipids. In addition, transcriptomics and metabolomics study showed that Abplatin(IV) significantly disturbed the purine metabolism pathway. Conclusions: This research highlighted the development of Abplatin(IV) and the use of multi-omics for the mechanism elucidation of prodrug, which is the key to the clinical translation of prodrug. Graphical